Literature DB >> 1587432

Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension.

G La Villa1, J M Salmerón, V Arroyo, J Bosch, P Ginés, J C García-Pagán, A Ginés, M Asbert, W Jiménez, F Rivera.   

Abstract

Failure to escape from mineralocorticoids in compensated cirrhosis is considered a major argument supporting the overflow theory of ascites. To assess the frequency and mechanism of mineralocorticoid escape in cirrhosis, 9-alpha-fluorohydrocortisone (0.6 mg/day) was administered to 19 patients with compensated cirrhosis, portal hypertension, and no history of ascites who were able to maintain sodium balance on a 250 mmol Na+ diet. Fifteen patients (78.9%) escaped from mineralocorticoids, while 4 patients (21.1%) did not escape and developed ascites. Patients who did not escape had significantly higher cardiac index (4.97 +/- 0.42 vs 3.46 +/- 0.21 L.min-1.m-2) and lower peripheral vascular resistance (485.9 +/- 37.5 vs. 665.8 +/- 32.9 dyne.s.cm-5/m2) than those who escaped. Hepatic venous pressure gradient was not significantly different. The escape phenomenon was associated with a significant increase in mean arterial pressure, creatinine clearance, and atrial natriuretic factor and suppression of plasma renin activity. All of these parameters showed minimal or no changes in patients who did not escape. These results indicate that failure to escape from mineralocorticoids is uncommon in patients with compensated cirrhosis, is related to an inadequate expansion of effective plasma volume due to the accumulation of ascites, and occurs in patients with marked peripheral arteriolar vasodilation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1587432     DOI: 10.1016/0016-5085(92)90340-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

2.  Pathogenetic background for treatment of ascites and hepatorenal syndrome.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  Hepatol Int       Date:  2008-09-20       Impact factor: 6.047

Review 3.  Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

Authors:  Amirali Masoumi; Fernando Ortiz; Jai Radhakrishnan; Robert W Schrier; Paolo C Colombo
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

4.  Sodium homeostasis with chronic sodium loading in preascitic cirrhosis.

Authors:  F Wong; P Liu; L Blendis
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 5.  Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis.

Authors:  R W Schrier; M Niederberger
Journal:  West J Med       Date:  1994-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.